Today I am introducing Donafenib, a new first-line targeted therapy for liver cancer, to the majority of liver cancer patients. Donafenib mesylate tablet (Donafenib) is a new type of multi-kinase inhibitor, which is a targeted drug developed by China. Pharmacological studies have shown that Donafenib can simultaneously inhibit the activity of multiple receptor tyrosine kinases such as VEGFR and PDGFR, as well as directly inhibit various Raf kinases and inhibit the downstream Raf/MEK/ERK signaling pathway to inhibit tumor cell proliferation and tumor blood vessel formation, exerting dual inhibition and multi-target blocking anti-tumor effects. The ZGDH3 study is the first completed Phase II/III clinical trial in China to evaluate donafinib for the first-line treatment of advanced hepatocellular carcinoma, enrolling 668 patients from March 2016 to April 2018, the largest number of first-line advanced hepatocellular carcinoma patients enrolled in a clinical trial in China to date. At the 56th Annual Meeting of the American Society of Oncology (ASCO 2020), which just concluded this year, the investigators presented the latest ZGDH3 research results to the world through an oral presentation, demonstrating the breakthrough progress of donafinil in targeted therapy for liver cancer. The ZGDH3 study randomized patients 1:1 to the Donafenib group (0.2g orally twice daily) and the Sorafenib group (0.4g orally twice daily). The study results showed that the primary endpoint of overall survival (OS) was better in the Donafenib group than in the control (sorafenib) group. Median overall survival (mOS) reached 12.1 months in the donafenib group compared to 10.3 months in the sorafenib group, a difference of 1.8 months. The risk of patients in the donafinib group decreased by 17% compared to the sorafenib group. With regard to safety, adverse reactions were essentially similar in both groups. Common adverse reactions in the donafenib group included skin reactions in the hands and feet (50.5%), diarrhea (36.6%), elevated aspartate aminotransferase (40.5%), elevated blood bilirubin (39.0%), and decreased platelet count (37.8%). Compared with patients in the sorafenib group, donafenib was significantly lower than the sorafenib group in both serious adverse reactions and adverse events leading to dose reduction or suspension. Donafinib is the first molecularly targeted drug with better survival than sorafenib in a large phase III clinical trial in advanced hepatocellular carcinoma treatment in 12 years. the ZGDH3 study showed that donafinib improved the survival of patients with advanced hepatocellular carcinoma compared to sorafenib, and was safe and well tolerated. Zeg King Pharmaceutical has already submitted a new drug marketing application to the New Drug Review Center of the State Drug Administration (NMPA). Donafinib is expected to become the first-line targeted therapy for advanced liver cancer in the future, benefiting more patients with advanced liver cancer.